This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
People with epilepsy are at a higher risk of premature death and suicide is one of the main culprits. It is well-recognized that suicide is more common in people with epilepsy, although estimates vary considerably concerning the magnitude of the risk. A recent meta-analysis estimated the overall standardized mortality ratio (SMR) for suicide in epilepsy as 3.3 (95% confidence interval 2.8-3.7). The SMR, however, ranges between 2.1 for people with newly diagnosed epilepsy in the community and 13.9 in those following temporal lobe resections.1 The Food and Drug Administration (FDA) issued an alert regarding an excess risk of suicidality in people taking antiepileptic drugs (AEDs) in 2008.2 The FDA had previously asked drug companies to submit data from placebo-controlled trials of AEDs, regardless of indication, provided that at least 30 patients were involved in such trials. A meta-analysis was then carried out by the FDA and it suggested an overall increased risk for suicidal behavior or ideation. As a result, manufacturers of AEDs were asked to include a warning in their labeling and develop a medication guide for patients, informing them of the risks of suicidal thoughts or behaviors.3
Some have suggested that the FDA's concern might be excessive4,5; that …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen